Metaloproteinazy macierzy MMP-2 i MMP-9 w surowicy pacjentów z cukrzycą typu 2

• Authors: Prystupa Andrzej , Kancik Emilia , Dyczko Monika , Dzida Grzegorz , Wójtowicz Tomasz , Kurzepa Jacek , Grabowska Aneta , Toruń-Jurkowska Anna , Stepulak Andrzej , Mosiewicz Jerzy
• Languages of publication: PL

Keywords

PL

metaloproteinazy MMP-2; MMP-9; cukrzyca typu 2.

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2011
• Issue: 2
• Pages: 229-232

Contributors

author

Prystupa Andrzej

author

Kancik Emilia

author

Dyczko Monika

author

Dzida Grzegorz

author

Wójtowicz Tomasz

author

Kurzepa Jacek

author

Grabowska Aneta

author

Toruń-Jurkowska Anna

author

Stepulak Andrzej

author

Mosiewicz Jerzy

References

• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69: 562–573.
• Bogaczewicz J, Chodorowska G, Krasowska D. Rola metaloproteinaz macierzy i tkankowych inhibitorów metaloproteinaz w progresji nowotworów skóry a nowe strategie farmakologicznej inhibicji metaloproteinaz macierzy. Prz Dermatol 2004; 91: 153–160.
• Owen KR , Groves ChJ, Hanson RL, et al. Common variation in the LMNA gene (encoding lamin A/C) and type 2 diabetes.Diabetes 2007; 56: 879–883.
• The effect of intensiva treatment of diabetes on development and progression of long-term complications in insulin- -dependent diabetes mellitus. The Diabetes Control and Complications trial Research Group. N Eng J Med 1993; 329:977–986.
• G haragozlian S, Svennevig K, Bangstad HJ, et al. Matrix metalloproteinases in subjects with type I diabetes. BMC Clin Pathol 2009; 9: 7–11.
• Derosa G, Avanzini MA, Geroldi D, et al. Matrix metalloproteinases 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabets Res Clin Pract 2005; 70: 119–125.
• Derosa G, Ferrari I, D’Angelo A, et al. Matrix metalloproteinases-2 and -9 levels in obese patients. Endothelium 2008:15; 219–224.
• Bellosta S, Gomaraschi M., Canavesi M, et al. Inhibition of MMP-2 activation and release as a novel mechanism for HDL-induced cardioprotection. FEBS Letters 2006; 580: 5974–5978.
• Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–21494.
• Lee SW, Song KE , Shin DS, et al. Alternations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabet Res Clin Pract 2005; 69: 175–179.Z